shortage of vascular surgeons, but if we diminish the number of training programs by centralizing cases, what trainee will want to go to a hospital where the vascular surgeons refer complex aortic cases elsewhere? Such a policy will certainly result in fewer training programs, unless the fellows at the low-volume hospitals are shipped out for months at a time to the high-volume hospitals. But we all agree we must do what is best for our patients.
Quick summary of antiplatelet agents for vascular surgeons: (1) give aspirin or clopidogrel for symptomatic patients with lower extremity arterial disease and carotid stenosis and after arterial surgery and (2) give both after endovascular interventions Antiplatelet Therapy for Peripheral Artery Disease Melfi R, Ricottini E. Cardiovasc Diagn Ther 2018;8:663-77.
Study design: A review was conducted of registries, randomized trials, and meta-analysis publications from PubMed between 1994 and 2018 and on-line clinical trials in 2018.
Key findings: For patients with lower extremity arterial disease, recommendations include the following: asymptomatic, no antiplatelet agents (especially diabetics) vs aspirin or clopidogrel alone; symptomatic patients and postsurgical intervention, aspirin or clopidogrel alone; after endovascular intervention, both for 1 month.
For patients with carotid stenosis, recommendations include the following: asymptomatic >50% stenosis, aspirin alone; symptomatic patients, aspirin or clopidogrel alone (although some studies showed that dual treatment is better); postsurgical intervention, aspirin or clopidogrel alone (clopidogrel may slightly decrease the perioperative stroke rate but may slightly increase the bleeding rate); after endovascular intervention, dual treatment for 1 month.
The authors also concluded that there is no significant relative risk reduction for cardiovascular death, myocardial infarction, or stroke with different doses of aspirin vs placebo for lower extremity arterial disease. Some studies of lower extremity occlusive disease have suggested that ticagrelor, a reversible P2Y 12 antagonist, may be more beneficial than clopidogrel, but this remains controversial. Oral anticoagulants are not beneficial for prevention of neurologic events due to carotid stenosis.
Conclusion: The greatest evidence showing the benefit of antiplatelet agents in reducing cardiovascular events is from large trials of coronary artery disease.
Commentary: It is very difficult to summarize the vast literature on this topic. The preceding comments are a brief summary of the authors' findings. For the interested reader, the article provides an in-depth summary of antiplatelet treatment of lower extremity arterial disease and carotid stenosis.
Will common femoral endarterectomy be of only historic interest in the future? 
